- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 08:46 | Ambrose Healthcare fortifies rare disease pipeline on AM-Pharma takeover | ||
| Mo | Roche's Enspryng nets a second indication on FDA eye disease approval | ||
| Mo | MHRA could allow schools to hold reserves of nasal adrenaline spray | ||
| Mo | FDA approves Viatris' Ryzumvi for adult presbyopia | ||
| Mo | Estuary secures $103m to advance kidney disease gene therapies | ||
| Fr | Lilly's Foundayo wins EMA panel backing for obesity and type 2 diabetes | ||
| Fr | OrbiMed raises $3bn to back global life science players | ||
| Fr | AstraZeneca and insitro forge $1.5bn AI-powered cardiometabolic partnership | ||
| Fr | Acta Pharmaceuticals raises $24m for Alzheimer's therapies | ||
| Fr | Transcripta Bio, Mayo Clinic join force on ALS therapies | ||
| Do | Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers | ||
| Do | Rare disease regulation reaches "inflection point" with new FDA framework | ||
| Do | QCi and INmune Bio partner to study XPro in Alzheimer's | ||
| Do | ImmunityBio's bladder cancer drug, Anktiva lands US label expansion | ||
| Do | Alentis and PinotBio partner to develop claudin-1 oncology ADCs | ||
| Mi | Zealand Pharma pens $1.2bn AI obesity drug discovery pact with Generate | ||
| Mi | MHRA homes in on personalised healthcare and tech in new 2030 strategy | ||
| Mi | Charles River partners with Magellan Stem Cells on cell therapy | ||
| Mi | Pfizer partners with Enodia Therapeutics in $500m drug deal | ||
| 13.10. | Tremfya rescues J&J's immunology sales to fuel strong Q3 | ||
| 13.10. | China's NMPA clears Foresee's Camcevi 42 mg for prostate cancer | ||
| 13.10. | Southern Research secures NIH funding for drug testing hub | ||
| 12.10. | FDA approves Teva's monthly injection of olanzapine for schizophrenia | ||
| 12.10. | FDA approves Asahi Kasei's Hovilpri for refractory HSV | ||
| 12.10. | Perceptive, Nucleus partner to support radiopharmaceutical development |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.